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Abstract 
The Objective of this paper is to investigate the profile changes of Amyloid Beta (Aβ) levels in the blood serum 
using AmyloidASerum (SAA)Mouse ELISA Kit and histopathological image of hippocampal tissue in mice 
injected with amyloid beta-protein (Aβ) fragment 1-42. 
------------------------------------------------------------------------ 
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Wistar rats were randomly selected and were divided into two cages. First Cage contained three mice which 
were injected Aβ1-42 peptide in the intracerebroventricullar (ICV) area with each dose of 0.2 µg, 0.13 µg and 
0.1 µg. While the second cage contained three mice which were injected Aβ1-42 peptide in intraperitoneal (IP) 
area with each dose of 0.2 µg, 0.13 µg and 0.1 µg. Observation was done in a month. SAA  mouse ELISA Kit 
Test and histopathologic image were used to detect Aβ1-42 peptide levels and the accumulation of  amyloid 
plaques layer formation on the extracellular (senile) and neurofibrillary tangles (NFT) in the intracellular. 
profile changes showed that the injection of 0.2 µg peptide Aβ1-42 in the intracerebroventricullar(ICV)area 
increased  Aβ levels compared to other doses both in the ICV and IP areas. PA results showed hypoxia state on 
nerve cells followed by vacuoles shrinkage in a large number of cells at 0.2 µg injection dosage in the ICV area. 
The results presented showed the importance of the establishment of Aβ1-42 peptide injection doses in 
experimental animals to build a more complete understanding of the molecular mechanisms result of Aβ1-42 
peptide exposure in injected mice in which the sign shown resemble Alzheimer's disease sign. Thus, various 
research efforts trials of the drug as well as natural ingredients intended for AD treatment can be growing. 
Keywords: amyloid beta; intraperitoneal; intracerebroventricullar; alzheimer's disease. 
1. Introduction 
Alzheimer's Disease (AD) was first discovered by Alois Alzheimer in 1906, a Germany’neurologist who in one 
occasion when undergone an autopsy found set of characteristic lesions in the brain, AD in a prior diagnosis lead 
to elimination before the final death.Overall damage result in dementia that can lead to stroke, brain tumors and 
other degenerative diseases [1]. Alzheimer's disease (AD is a common cause of dementia in the elderly (the 
elderly), which 7% -10% happens in individuals over the age of 65 years old and 40% in individuals over 80 
years old [2]. Alzheimer's Drug Discovery Foundation ( ADDF) estimated that one in three people in age group 
of 80 years old will develop the disease. Even in 2025, the cases will reach 34 billion [3]. Alzheimer's Disease 
(AD) is a neurodegenerative disease that occurs progressively which characterized by cognitive decline and 
memory loss. Pathological characteristic changes of Alzheimer's Disease (AD) usually include differences in 
neuronal loss or apoptosis level, senile plaques formed by deposits of beta amyloid in extracellular and 
intracellular neurofiblillary tangles (NFT), from hiperfosforilasi microtubule of atau protein (Tau) group in the 
brain. With the rapid growth in the elderly population in the world, the incidence of the number of people with 
AD also increased from year to year [4]. Characteristic lesions in the brains of AD is characterized by the 
presence of extracellular neuritic plaques (senile) and intracellular neurofibrillary tangles section which spread 
throughout the area of the cerebral cortex, especially found in large quantities in the hippocampus. Neuritic 
plaques consist of central core form in an extracellular, with compact form, fibrous protein known as beta 
amyloid (Aβ) surrounding the dendritic and axonal nerve endings. Neurofibrillary tangles is an abnormal solid 
cluster, such as filament in pairs similar to helic form that accumulates in the cell body which can be affected by 
neurons [5]. Many etiologic factors which may cause the occurrence of AD such as a genetic mutation, a 
susceptible gene and environmental factors that support the accumulation and formation of insoluble Aβ and 
hyperphosphorylated tau. An animal model that shows AD characteristics has been developed using the 
injection of beta amyloid (Aβ) in the region of mice’ ICV [6,7,8]. Various techniques have been developed to 
detect the characteristic of Alzheimer's disease in patients and animal models. Among them use ultramicroscopy 
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to see an ideal images for monitoring deposits β-amyloid plaque state in experimental animals’ brains. Those 
become a basis for studying the relationship between tissue degeneration of neurons in the cerebral β-
amyloidosis and for asessing Aβ against therapeutic targets. In another reference, cDNA microarray was used to 
look at changes in guine pig cerebral cortex gene expression profile after injected by beta protein fragment (Aβ) 
25-35, others use water Mize Moris test (MWM) for measuring spatial memory and learning in Alzheimer's 
disease guine pig model [4]. In this study, we used the Amyloid A Serum (SAA) Mouse ELISA Kit parameters 
to measure the levels of beta-amyloid (Aβ) in the blood serum of experimental animals and used anatomic 
pathology examination(PA) to see the accumulation layer formation of amyloid plaques and neurofibrillary 
tangles (NFT). Specific knowledge about the causes of neurodegenerative etiology is as important pace setter 
for the development of various kinds of drugs for the neuroprotective treatment. There for, it required a means 
of making animal Alzheimer's disease modeling to test various kinds of drugs both chemical and phytotheraphy. 
2. Materials and Method 
Experimental procedures carried out in Molecular Microbiology and Immunology Laboratory, Medical Faculty, 
HasanuddinUniversity, Makassar. 
2.1. Drug 
Amyloid1-42 beta peptide (Aβ1-42 peptide) was derived from Abcam [9]. Amyloid β (1-42) human peptide was 
dissolved at a concentration of 1 µg / ml 100% HFIP (1,1,1,3,3,3-hexafluoro-2-propanol). The solution was 
further incubated at room temperature for 1 hour and occasionally rotated sufficiently. Next, the solution was 
vibrated for 10 minutes in a water tube sonicator. The solution of peptide / HFIP then dried under nitrogen gas 
stream. 100% DMSO was used to mix the peptide. The solution was further incubated at room temperature for 
12 minutes and occasionally been rotated. Finally the solution subsequently formed into small volumes and 
stored at temperature -80 ° C. To use the solution add 500-1000 mL D-PBS (depending on the final 
concentration used) into the peptide stock solution and incubation in room temperature to provide an 
opportunity for the peptide not to agglomerate. Researcher estimated plan in determining the dose calculation 
was as follows: 
1 µg / ml = 1000 ug / ml = 1000 g / 1000 mL = 1 µg / ml 
10 g = 10μl 
1: 500 ≈ 1: 750 ≈ 1: 1000 
[For 1: 500] ie; 10 mL + 490 mL of PBS → 10/500 x 10 µg = 0.2 µg / 10μl 
[For 1: 750] ie; 10 mL + 740 mL of PBS → 10/750 x 10 µg = 0.13 µg / 10μl 
[For 1: 1000], namely; 10 mL + 990 mL of PBS → 10/1000 x 10 µg = 0.1 µg / 10μl 
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2.2. Animal Model and Aβ1-42 peptide injection 
Six wistar rats was adapted for 1 week in the laboratory (in a standardized cage) at room temperature (25 ° C ± 2 
°), dark and light cycles (12/12 h), fed and watered according to ad libitum [10]. Selection of experimental 
animals done randomly, after the adaptation period was completed then we made experimental animal models of 
Alzheimer's Disease (AD) which were placed on stereotaxic apparatus. Later in the cage I Aβ1-42 peptide 
injection was slowly injected over 10 minutes using a 10 mL microsyringe on intracerebroventricular (ICV) 
with each dose of 0.2 µg, 0.13 µg and 0.1 µg. While in the cage II, Aβ1-42 peptide was injected in 
intraperitoneal (IP) with each dose of 0.2 µg, 0.13 µg and 0.1 µg, then observed for 21 days, during the time, we 
did weighing and blood sampling from a vein in the animal tail [11] amounted to 0.1 ml using a hemetocrate 
syringe [12] on days 0,1,7,14 and day 21 with the aim to see fluctuations in Beta amyloid exposure. Blood taken 
5 times (days 0,1,7,14 and 21) were collected and centrifuged to obtain serum. Serum then stored in a sterile 
tube and in refrigerator -20 ° C in temperature [11]. Until the time of measurement was finished,we measured 
the levels of Aβ1-42 peptide using Amyloid A Serum (SAA) ELISA Kit Mouse Test, where as on day 21 when 
the last day of the blood drawn, the experimental animals ware sacrified and hippocampal brain tissues were 
taken for PA examination, to see the accumulation of amyloid plaque formation in the extracellular part (senile) 
and neurofibrillary tangles (NFT) in the intracellular part. 
2.3. Procedures for Aβ Levels 
In this measurement method, amyloid A serum from the sample to be reacted with the antibody anti-serum 
amyloid A, which will be absorbed on the surface of the polystyrene microtiter in wells. After eliminating 
protein which was not attached to the antibody by washing mecanism, then amyloid A Serum Antibody were 
conjugated with the addition of horseradish peroxidase (HRP). The enzyme  in labeled antibody formed a 
complex amyloid A bond, followed by the washing process, the amount of enzyme which binds to the complex 
was measured by adding a chromogenic substrate 3,3 ', 5,5'-tetramethylbenzidine (TMB). The quantity of 
enzyme bonding varies proportionally to the concentration of amyloid A serum in the samples tested. 
Absorbance at 450 nm was one measurement of amyloid A serum concentrations in the samples tested. The 
quantity of amyloid A serum in the samples tested could be inter-polarisated from standard curves which were 
constructed and corrected for diluted of samples [13]. 
Summary ab157723- Amyloid A  Serum (SAA) ELISA Kit Mouse Measurement from 'abcam were as follows: 
1) Eliminate exactly the amount of the antibody that coated well, balance the entire reagent at room 
temperature. Prepare all the reagents, samples and standards. 
2) Add standard or sample in each well used, then incubation process at room temperature. 
3) Asspirated and washed each well, then add HRP previously prepared and labeled second antibody 
detectorincubation process at room temperature. 
4) Asspirated and washedeach well, then add the chromogen substrate solution into each well. 
Furthermore slowly log visible color development. 
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2.4. Sample Preparation 
General Sample information. Measurements for the quantification amyloid Aserum in the sample, for each 
sample were diluted before use. For one determination stage, a dilution of 1 / 1,000 was appropriate for most 
samples of serum / plasma. For the absolute quantification sample results lies outside the standard curve, 
dilution was less than or greater than the existing sample. If the level of the sample was doubt, a serial dilution 
with one or two representative samples earlier then undergo running with a plate that had been recommended. 
To prepare the 1 / 1.000 dilution of the sample, transfer 5 mL of the sample to 495 mL of 1x diluents. Here give 
1/100 dilution. Next, made 1/100 dilution of the sample by removing30 mL up to 270 mL of 1x diluents. We 
should have a 1 / 1,000 dilution of our sample, fully mixed at each of these stages. 
2.5. Measurement procedure 
Balance the entire material ingredients and prepare reagents at room temperature before use. It is recommended 
to measure all the standards, control and samples in duplicate. 
1) Pipette 100 mL of each standard, including zero control in duplicate, into a well fitted. 
2) Pipette 100 mL samples (in duplicate) into well fitted. 
3) Incubate the microtiter plate at room temperature for 60 (60 ± 2) minutes. Close the plate during 
incubation. 
4) Continue incubation, aspiration materials from wells 
5) Fill each well with wash buffer dilution one time appropriately then aspirations. Repeat 3 times, to 
entirely do the washing for 4 times. If washing by hand, fill out the charging each well with wash 
buffer, subsequently reversed plate pour the contents into a cleaning container. Continue the process on 
the well carefully on absorbent paper which was intended to remove residual buffer. Repeat until 3 to 4 
times entirely on whasing process. 
6) Pipette 100 uL precisely conjugate 1X antibody enzyme into each well. Incubation at room temperature 
for 30 (30 ± 2) minutes. Protect the plate with dark cover during incubation process. 
7) Wash blot on well 
8) Pipette 100 uL of TMB substrate solution into each well 
9) Incubation in the dark at room temperature for 10 minutes 
10) Add 100 mL stop solution to each well 
11) Absorbance determination (450 nm) in each well. Calibration plate reader to establish specifications 
2.6.Calculation 
Standard readings duplication equated to each standard, sample and blank control. Subtract blank control of the 
entire average results. Results of average standard that has been set as opposed to the concentration and draw the 
best smooth curve pierce point to establish a standard curve. Most software plate reader or graph can be set as 
value and the actual arch. Four parameters of the algorithm (4PL) is usually available. Other equations can be 
tested for accuracy (such as linear, semi-log, log / log, 4-logisticparameter). Taking into account the protein 
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concentration to something unknown and control samples from the standard curve that has been determined. 
Samples generate large signals from standard and in further dilution by 1X in  incubation buffer and then re-
analyzed, then doubling the concentration obtained from the appropriate dilution factor 
2.7. PA inspection procedures 
For  PA inspection used staining hematoxyllin eosyn (HE) technique, in which the brain tissue embedded into 
fixative consentrate containing 4% paraformaldehyde for 24 hours, and then dipped in paraffin, were cut using a 
microtome with intervals of 5 mm along the coronal plane [14]. 
3. Results 
Results Analysis Of Aβ1-42 Peptide Injection Using Amyloid A  Serum (SAA) ELISA Kit MouseTests: 
Effect of Aβ injection from the measurement Aβ1-42 peptide levels value using Amyloid A Serum (SAA) 
Mouse ELISA Kit Test, can be seen in the following table 1 below: 
Table 1: Aβ1-42 peptide levels value 
Injection Areas& 
Animal Model 
Injection in  
The Intraperitoneal (IP) Area 
Injection In  
The intracerebroventricullar (ICV)  Area 
1  2  3  4  5  6  7  8  9  10  11  12  
SO (A)  0,766  0,783  0,704  0,682  0,721  0,742  0,744  0,746  0,729  0,736  0,779  0,786  
S1 (B)  1,485  1,407  1,423  1,409  1,359  1,365  2,306  2,319  2,307  2,318  2,394  2,369  
S2 (C)  1,682  1,669  1,606  1,602  1,667  1,669  2,471  2,443  2,464  2,455  2,589  2,578  
S3 (D)  1,812  1,858  1,832  1,853  1,865  1,873  2,544  2,539  2,602  2,616  2,719  2,709  
S4 (E)  2,011  2,037  2,068  2,079  2,072  2,052  2,727  2,824  2,771  2,787  2,804  2,808  
Blank (F)  0,065  0,098  0,074  0,063  0,073  0,068  0,069  0,066  0,068  0,081  0,071  0,068  
Blank (G) 0,068  0,063  0,061  0,077  0,064  0,063  0,069  0,071  0,063  0,076  0,066  0,065  
Blank (H) 0,069  0,071  0,073  0,067  0,067  0,071  0,068  0,074  0,083  0,069  0,066  0,086  
According to Table 1 results above showed the data before Aβ1-42 peptide injection on days 0, we do blood 
sampling to 0 (called S0) and continued injection of Aβ1-42 peptide. The next day was the day after the 
injection / 24 hours post-injection (called S1), continued day 7 (called S2) and day 14 (called S3), and the last 
on day 21 (called S4) which was the last week , While the code 1 up to 12 were codes description for 
experimental animals at varying doses given: 
1 s / d 6: 1 & 2 (Yellow Code.Head = 0.2 µg)) 
 3 & 4 (Yellow Code.The Back = 0.13 µg)) 
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2016) Volume 28, No  2, pp 90-99 
96 
 
5 & 6 (Yellow Code.Tail= 0.1 µg)) 
7 s / d 12: 7 & 8 (Yellow Code.Head= 0.2 µg)) 
 9 & 10 (Yellow Code.The Back= 0.13 µg)) 
11 & 12 (Yellow Code.Tail= 0.1 µg)) 
Data results in Table 1 above were made in duplicate for each dose, then from the same data also were made  
mean / average calculation on each of these doses and the results can be seen in the following table 2 below. 
Mean Result Of “β-Amiloid Levels” Using Elisa KIT 
Table 2 : Mean / average Values of beta amyloid measurements in the area of ICV and IP 
 Injection In Intraperitoneal (IP) Area Injection intracerebroventricullar (ICV) Area 
(1+2)/2 (3+4)/2 (5+6)/2 (7+8)/2 (9+10)/2 (11+12)/2 
SO (A) 0,7745 0,693 0,7315 0,745 0,7325 0,7825 
S1  (B) 1,446 1,416 1,362 2,3125 2,3125 2,3815 
S2  (C) 1,6755 1,604 1,668 2,457 2,4595 2,5835 
S3  (D) 1,835 1,8425 1,869 2,5415 2,609 2,714 
S4  (E) 2,024 2,0735 2,062 2,7755 2,779 2,806 
• From Table 2 above showed that the injection of the peptide in the area Aβ1-425 ICV at a dose = 0.2 µg seen 
an increase compared to the number value in the area of IP and ICV with different dosage. The final result 
obtained that injection of Aβ1-42 peptide in the area intracerebroventricular ( ICV ) at a dose of 0.2 µg appears 
to be rising significantly compared with a dose of 0.13 µg and 0.1 µg in both ICV area and in the area of IP . To 
see the Figure clearly can be seen in the following chart  
Values Chart Aβ1-42 peptide Levels
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Figure 1: Values Chart Aβ1-42 peptide Levels 
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The results of the analysis of histopathologic picture / PA in hippocampal brain tissue were as follows: 
 
Figure 2a           Figure 2b                         Figure 2c 
Figure 2: analysis of histopathologic picture / PA in hippocampal brain tissue 
In the figure 2a, 2b and 2c with dose of 0.1 µg, 0.13 µg, 0.2 µg ICV injection area looked their 
hypooxygenization (indicated by the white circle surrounding a nucleus) were increasing and were visible in 
Figure 2c, namely at a dose of 0.2 µg followed by the formation of beta amyloid plaques (marked with arrows) 
as well as the contraction of karyopiknosis cell. 
4. Discussion 
Research has been done showing that injection of Aβ1-42 peptide in the area intracerebroventricular (ICV) in 
the Wistar rat can induce pathological symptoms of Alzheimer's disease. The Significant Symptoms in patients 
with AD is the accumulation of Aβ-peptide in the brain, Amyloid Beta (Aβ) peptide is a toxic produced by 
endoproteolytic of amyloid precursor protein. Insoluble Beta amyloid is normally accumulated in the brain 
parenchyma and blood vessels of patients with AD [15]. Frautschy and his colleagues in their research said that 
little amyloid can be formed 30 days after injection into the cerebral ventricle Aβ1-40 [16]. Some theory and 
journal references said that typical characteristics of AD brain is characterized by the presence of lesions caused 
by extracellular neuritic plaques (senile) and intracellular neurofibrillary tangles part which spread throughout 
the area of the cerebral cortex, especially found in large quantities in the hippocampus [5]. The initial amyloid 
plaques can be detected at week 4 to week 6 in the area of the neocortex [17]. Staining technique using 
hematoxylin eosin (HE) was used to analyze the histopathological damage to the hippocampus area [18]. In 
addition to techniques HE, technique of staining may be used such as congo red, silver staining and choline 
acetyl transferase (CHAT), the results showed that the cognitive abilities of the experimental animals model 
suffered damage to the neurons and occurs karyopiknosis, and even further the formation of senile plaques (SP) 
and neurofibrillary tangles (NFT) in the cortex and hippocampus, choline acetyl transferase decreased then 
trigger the increased  in Aβ. Overal,l these changes lasting more than 3 months [19]. So it can be tested for an 
extended time in the future study. 
5. Conclusion 
The results presented showed the importance of the establishment of Aβ1-42 peptide injection doses in 
experimental animals to build a more complete understanding of the molecular mechanisms result of Aβ1-42 
peptide exposure in injected mice in which the sign shown resemble Alzheimer's disease sign. Thus, various 
research efforts trials of the drug as well as natural ingredients intended for AD treatment can be growing. 
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